• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

九种人类白细胞抗原（HLA）I类等位基因对黑色素瘤肿瘤中表达的11种抗原具有全能抗性。

Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors.

作者信息

Georgopoulos Apostolos P, James Lisa M, Sanders Matthew

机构信息

The HLA Research Group, Brain Sciences Center, Department of Veterans Affairs Health Care System, Minneapolis, MN, USA.

Department of Neuroscience, University of Minnesota Medical School, Minneapolis, MN, USA.

出版信息

Cancer Inform. 2024 Aug 27;23:11769351241274160. doi: 10.1177/11769351241274160. eCollection 2024.

DOI:10.1177/11769351241274160
PMID:39206277
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11350539/
Abstract

OBJECTIVE

Host immunogenetics (Human Leukocyte Antigen, HLA) play a critical role in the human immune response to melanoma, influencing both melanoma prevalence and immunotherapy outcomes. Beneficial outcomes hinge on the successful binding of epitopes of melanoma antigens to HLA Class I molecules for an effective engagement of cytotoxic CD8+ lymphocytes and subsequent elimination of the cancerous cell. This study evaluated the binding affinity and immunogenicity of HLA Class I to melanoma tumor antigens to identify alleles best suited to facilitate elimination of melanoma antigens.

METHODS

In this study, we used freely available software tools to determine the binding affinity and immunogenicity of 2462 reported HLA Class I alleles to all linear nonamer epitopes of 11 known antigens expressed in melanoma tumors (TRP2, S100, Tyrosinase, TRP1, PMEL(17), MAGE1, MAGE4, CTA, BAGE, GAGE/SSX2, Melan).

RESULTS

We identified the following 9 HLA Class I alleles with very high immunogenicity and binding affinity against all 11 melanoma antigens: A02:14, B07:10, B35:10, B40:10, B40:12, B44:10, C07:11, and C07:13, and C*07:14.

CONCLUSION

These 9 HLA alleles possess the potential to aid in the elimination of melanoma both by themselves and by enhancing the beneficial effect of immune checkpoint inhibitors.

摘要

目的

宿主免疫遗传学（人类白细胞抗原，HLA）在人类对黑色素瘤的免疫反应中起关键作用，影响黑色素瘤的患病率和免疫治疗结果。有益的结果取决于黑色素瘤抗原表位与HLA I类分子的成功结合，以有效激活细胞毒性CD8 +淋巴细胞并随后消除癌细胞。本研究评估了HLA I类与黑色素瘤肿瘤抗原的结合亲和力和免疫原性，以确定最适合促进消除黑色素瘤抗原的等位基因。

方法

在本研究中，我们使用免费的软件工具来确定2462个已报道的HLA I类等位基因与黑色素瘤肿瘤中表达的11种已知抗原（TRP2、S100、酪氨酸酶、TRP1、PMEL(17)、MAGE1、MAGE4、CTA、BAGE、GAGE/SSX2、Melan）的所有线性九肽表位的结合亲和力和免疫原性。

结果

我们鉴定出以下9种对所有11种黑色素瘤抗原具有非常高免疫原性和结合亲和力的HLA I类等位基因：A02:14、B07:10、B35:10、B40:10、B40:12、B44:10、C07:11、C07:13和C*07:14。

结论

这9种HLA等位基因有潜力通过自身以及增强免疫检查点抑制剂的有益效果来帮助消除黑色素瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8344/11350539/db41f05e7cfe/10.1177_11769351241274160-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8344/11350539/db41f05e7cfe/10.1177_11769351241274160-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8344/11350539/db41f05e7cfe/10.1177_11769351241274160-fig1.jpg

相似文献

1
Nine Human Leukocyte Antigen (HLA) Class I Alleles are Omnipotent Against 11 Antigens Expressed in Melanoma Tumors.九种人类白细胞抗原（HLA）I类等位基因对黑色素瘤肿瘤中表达的11种抗原具有全能抗性。
Cancer Inform. 2024 Aug 27;23:11769351241274160. doi: 10.1177/11769351241274160. eCollection 2024.
2
Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors.黑色素瘤与人类白细胞抗原（HLA）：69种HLA I类等位基因在黑色素瘤肿瘤中表达11种抗原的免疫原性
Cancer Inform. 2023 May 22;22:11769351231172604. doi: 10.1177/11769351231172604. eCollection 2023.
3
Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities.使用源自肿瘤相关抗原的具有不同MHC结合亲和力的合成肽混合物刺激肿瘤反应性T淋巴细胞。
J Immunol Methods. 2003 May 1;276(1-2):103-19. doi: 10.1016/s0022-1759(03)00078-4.
4
Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma.123例黑色素瘤患者的肿瘤浸润性T淋巴细胞对与主要HLA - A等位基因相关的共享黑色素瘤抗原的识别。
J Immunother. 2000 Jan;23(1):17-27. doi: 10.1097/00002371-200001000-00004.
5
Elucidating the immunological effects of 5-azacytidine treatment in patients with myelodysplastic syndrome and identifying new conditional ligands and T-cell epitopes of relevance in melanoma.阐明5-氮杂胞苷治疗骨髓增生异常综合征患者的免疫效应，并鉴定黑色素瘤中相关的新条件配体和T细胞表位。
Dan Med J. 2015 Aug;62(8):B5144.
6
Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.肿瘤逃避免疫识别：HLA - A2黑色素瘤细胞表面表达缺失与6号染色体短臂的复杂重排相关。
Clin Cancer Res. 1996 Apr;2(4):641-52.
7
Extensive major histocompatibility complex class I binding promiscuity for Mycobacterium tuberculosis TB10.4 peptides and immune dominance of human leucocyte antigen (HLA)-B*0702 and HLA-B*0801 alleles in TB10.4 CD8 T-cell responses.广泛的主要组织相容性复合物 I 类结合混杂性用于结核分枝杆菌 TB10.4 肽，以及人类白细胞抗原 (HLA)-B*0702 和 HLA-B*0801 等位基因在 TB10.4 CD8 T 细胞反应中的免疫优势。
Immunology. 2010 Apr;129(4):496-505. doi: 10.1111/j.1365-2567.2009.03201.x. Epub 2009 Nov 25.
8
Immunodominance across HLA polymorphism: implications for cancer immunotherapy.HLA多态性中的免疫显性：对癌症免疫治疗的影响。
J Immunother. 1998 Jan;21(1):1-16.
9
The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles.MHC 呈递的磷酸肽全景为癌症免疫治疗提供了跨多个 HLA 等位基因的可操作共享肿瘤抗原。
J Immunother Cancer. 2023 Sep;11(9). doi: 10.1136/jitc-2023-006889.
10
Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships.迈向I类和II类小鼠主要组织相容性复合体-肽结合亲和力的预测：使用定量构效关系的计算机生物信息学逐步指南
Methods Mol Biol. 2007;409:227-45. doi: 10.1007/978-1-60327-118-9_16.

本文引用的文献

1
Allele Frequency Net Database.等位基因频率数据库。
Methods Mol Biol. 2024;2809:19-36. doi: 10.1007/978-1-0716-3874-3_2.
2
mRNA Cancer Vaccines: Construction and Boosting Strategies.mRNA 癌症疫苗：构建与增强策略。
ACS Nano. 2023 Oct 24;17(20):19550-19580. doi: 10.1021/acsnano.3c05635. Epub 2023 Oct 11.
3
Melanoma and Human Leukocyte Antigen (HLA): Immunogenicity of 69 HLA Class I Alleles With 11 Antigens Expressed in Melanoma Tumors.黑色素瘤与人类白细胞抗原（HLA）：69种HLA I类等位基因在黑色素瘤肿瘤中表达11种抗原的免疫原性
Cancer Inform. 2023 May 22;22:11769351231172604. doi: 10.1177/11769351231172604. eCollection 2023.
4
Immune Checkpoint Inhibitors - The Need for Innovation.免疫检查点抑制剂——创新的必要性。
N Engl J Med. 2023 Apr 20;388(16):1529-1532. doi: 10.1056/NEJMsb2300232.
5
SARS-CoV-2 in silico binding affinity to human leukocyte antigen (HLA) Class II molecules predicts vaccine effectiveness across variants of concern (VOC).SARS-CoV-2 在计算机上与人类白细胞抗原 (HLA) Ⅱ类分子的结合亲和力可预测针对关注变异株 (VOC) 的疫苗有效性。
Sci Rep. 2022 May 16;12(1):8074. doi: 10.1038/s41598-022-11956-5.
6
Deregulation of HLA-I in cancer and its central importance for immunotherapy.肿瘤中 HLA-I 的失调及其对免疫治疗的核心重要性。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2021-002899.
7
Neoantigen: A New Breakthrough in Tumor Immunotherapy.肿瘤免疫治疗新突破：新抗原
Front Immunol. 2021 Apr 16;12:672356. doi: 10.3389/fimmu.2021.672356. eCollection 2021.
8
Therapeutic cancer vaccines.治疗性癌症疫苗。
Nat Rev Cancer. 2021 Jun;21(6):360-378. doi: 10.1038/s41568-021-00346-0. Epub 2021 Apr 27.
9
A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors.癌症免疫疗法毒性综述：免疫检查点抑制剂。
J Med Toxicol. 2021 Oct;17(4):411-424. doi: 10.1007/s13181-021-00833-8. Epub 2021 Apr 7.
10
A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses.癌症免疫疗法毒性综述 II：过继细胞疗法、激酶抑制剂、单克隆抗体和溶瘤病毒。
J Med Toxicol. 2022 Jan;18(1):43-55. doi: 10.1007/s13181-021-00835-6. Epub 2021 Apr 5.